Results 71 to 80 of about 1,463,708 (228)

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network. [PDF]

, 2013
There is increasing evidence that opioid analgesics may interfere with tumour growth. It is currently thought that these effects are mediated by transactivation of receptor tyrosine kinase (RTK)-controlled ERK1/2 and Akt signalling.
Weingaertner, Inka Regine, Sarah Koutnik, Inka Regine Weingaertner, Koutnik, Sarah, Hermann Ammer, Ammer, Hermann   +5 more
core   +1 more source

Kappa opioid receptor activation alleviates experimental autoimmune encephalomyelitis and promotes oligodendrocyte-mediated remyelination

Nature Communications, 2016
Current treatments of multiple sclerosis are aimed at immunosuppression. Here the authors show that kappa opioid receptor is important for oligodendrocyte differentiation and myelination and the receptor agonists are protective in a mouse model of ...
Changsheng Du, Yanhui Duan, Wei Wei, Yingying Cai, Hui Chai, Jie Lv, Xiling Du, Jian Zhu, Xin Xie   +8 more
doaj   +1 more source

Natural product‐derived TRPM7 channel inhibitors in neurological injury: Mechanisms, pharmacological potential and translational challenges

British Journal of Pharmacology, EarlyView.
Disruption of intracellular ionic homeostasis is a convergent pathological feature across diverse neurological injuries and disorders, including ischaemic and haemorrhagic stroke, hypoxic–ischaemic brain injury, traumatic brain injury, epilepsy and brain tumour.
Xinyang Zhang, Hio Lam Ho, F. David Horgen, Andrea Fleig, Zhong‐Ping Feng, Hong‐Shuo Sun   +5 more
wiley   +1 more source

Nociceptin/orphanin FQ – NOP receptor system: novel genetic and pharmacological tools [PDF]

, 2012
The neuropeptide nociceptin/orphanin FQ (N/OFQ) selectively binds and activates the N/OFQ peptide (NOP) receptor. In cells expressing the NOP receptor N/OFQ inhibits cAMP accumulation and Ca2+ conductance and stimulates K+ currents.
Molinari, Stefano
core  

Effects of Selective and Mixed-Action Kappa and Delta Opioid Receptor Agonists on Pain-Related Behavioral Depression in Mice

Molecules
We recently developed a series of nalfurafine analogs (TK10, TK33, and TK35) that may serve as non-addictive candidate analgesics. These compounds are mixed-action agonists at the kappa and delta opioid receptors (KOR and DOR, respectively) and produce ...
S. Stevens Negus, Celsey M. St. Onge, Young K. Lee, Mengchu Li, Kenner C. Rice, Yan Zhang   +5 more
doaj   +1 more source

Neuropathic pain in cerebral palsy and related genetic conditions: A scoping review of prevalence, characteristics, and management

Developmental Medicine &Child Neurology, EarlyView.
Abstract Aim To map existing evidence on neuropathic pain in cerebral palsy (CP) and related genetic conditions, including prevalence, descriptors, assessment methods, and management. Method Following prospective registration, five databases (Ovid MEDLINE, Embase, CINAHL, Web of Science, Google Scholar) were searched in June 2025.
Aayushi Khillan, Sanya Verma, Hannah Yeomans, Karen Bau, Caitlin Doyle, Monica S. Cooper, David J. Amor, Carolyn Berryman, Adrienne Harvey   +8 more
wiley   +1 more source

Opioid Antagonists for Hedonic Liberation—Not All Is Over

Future Pharmacology
Recent Phase 3 clinical trials of selective kappa-opioid (KOP) receptor antagonists aticaprant and navacaprant failed to demonstrate sufficient clinical efficacy in treatment-resistant depression (TRD).
Farid Shagiakhmetov, Inna Shamakina, Viktor Kokhan, Evgeny Krupitsky   +3 more
doaj   +1 more source

Shared dysregulation of complement and phosphorylation pathways in the cerebrospinal fluid of encephalitis, Aicardi–Goutières syndrome, and autism

Developmental Medicine &Child Neurology, EarlyView.
Abstract Aim To identify shared and disorder‐specific molecular alterations across encephalitis, Aicardi–Goutières syndrome (AGS), and autism spectrum disorder (ASD) using cerebrospinal fluid (CSF) proteomics. Method In this cross‐sectional case–control study, mass‐spectrometry‐based proteomics was performed on archived CSF samples collected between ...
Omar H. Shadid, Peter G. Hains, Velda X. Han, Jingya Yan, Michael Griffiths, Ignatius Pang, Sushil Bandodkar, Phillip J. Robinson, Russell C. Dale   +8 more
wiley   +1 more source

Oral Status in Relation to Demographic, Socioeconomic, Medical and Psychosocial Risk Factors Among Outpatients in Addiction Treatment Centers, Stockholm, Sweden

International Journal of Dental Hygiene, EarlyView.
ABSTRACT Objective To investigate oral status in relation to demographic, socioeconomic, medical and psychosocial risk factors among outpatients receiving treatment for Substance Use Disorder (SUD). Methods This cross‐sectional study included 91 outpatients from Stockholm, Sweden. Oral status was assessed using the Decayed, Missing, Filled Teeth (DMFT)
Sonja Rafat, Stefan Borg, Gunnar Edman, Anders Hammarberg, Patricia De Palma   +4 more
wiley   +1 more source